WebDoctor Encyclopedia

Liver, bile ducts & pancreas

Acinar cell carcinoma of the pancreas

Acinar cell carcinoma is a rare pancreatic cancer that grows from the enzyme-making cells. It is often large when found, may raise blood lipase, and has a better outlook than common pancreatic cancer, with surgery, FOLFIRINOX and gene-matched drugs as options.

Medically reviewed Last reviewed October 21, 2026

What is acinar cell carcinoma of the pancreas?

Acinar cell carcinoma is an uncommon cancer of the pancreas. The pancreas has two main jobs. It makes digestive enzymes, which travel through ducts into the bowel, and it makes hormones such as insulin.

The enzyme-making cells are grouped in tiny clusters called acini. Acinar cell carcinoma develops from these cells, which is why it is different from the much more common pancreatic ductal adenocarcinoma.

Acinar cell carcinoma accounts for only a small fraction of pancreatic tumours, estimated at between 0.2% and about 4% depending on the series (Ikezawa et al., 2024). It affects men more often than women, usually in their 50s to 70s, but it can also occur in children.

These tumours are often large when found, with a typical size of around 5 cm, and they frequently sit in the head of the pancreas (Ikezawa et al., 2024). Some produce so much of the enzyme lipase that it leaks into the blood. This can cause painful fatty lumps under the skin and joint pain, a rare but striking pattern.

Compared with ductal adenocarcinoma, acinar cell carcinoma usually has a better outlook. Surgery is the main treatment when the cancer has not spread, but it often comes back afterwards. For advanced disease, chemotherapy is used, and many tumours carry gene changes such as BRCA1, BRCA2 or ATM, which can make platinum drugs and PARP inhibitors particularly useful.

1. Key facts at a glance

Feature Details
Type of cancer Carcinoma arising from the enzyme-producing (acinar) cells of the pancreas
How common Rare; roughly 1-2% of adult pancreatic tumours
Typical age Usually 50-70; occasionally children and teenagers
Sex More common in men
Typical size at diagnosis Around 5 cm
Usual site Head of the pancreas more often than body or tail
Blood test clue Raised lipase in a quarter to more than half of patients
Main treatment Surgery if localised; chemotherapy such as FOLFIRINOX if advanced
Outlook Better than ductal adenocarcinoma; recurrence is common

2. Types of acinar cell carcinoma

Type Description
Pure acinar cell carcinoma The usual form; cells show only acinar features
Acinar cell cystadenocarcinoma A rare form with large cystic spaces
Mixed acinar-neuroendocrine carcinoma Contains both acinar and neuroendocrine cells
Mixed acinar-ductal carcinoma Contains both acinar and ductal cancer cells
Acinar cell carcinoma outside the pancreas Very rarely arises in misplaced pancreatic tissue, for example in the stomach wall

Pancreatoblastoma, a childhood tumour, also shows acinar differentiation but is a separate disease.

How it differs from common pancreatic cancer

Feature Acinar cell carcinoma Ductal adenocarcinoma
Cell of origin Enzyme-producing acinar cells Duct-lining cells
Frequency Rare About 9 in 10 pancreatic cancers
Size at diagnosis Often large Often smaller
Appearance on scans Well-defined, solid, sometimes with dead or bleeding areas Ill-defined, infiltrating
Main gene changes BRCA1/2, ATM, APC/beta-catenin, BRAF fusions KRAS, TP53, CDKN2A, SMAD4
KRAS mutation Uncommon Present in over 90%
Outlook Better Poorer

3. Causes and risk factors

The cause is not known. Unlike ductal adenocarcinoma, there is no strong link with smoking or pancreatitis.

Factor Notes
Male sex More cases in men
Age Mostly middle-aged and older adults
Inherited BRCA1, BRCA2 or ATM variants Found in a proportion of patients; genetic counselling may be offered
Lynch syndrome Rare cases with mismatch repair defects
Familial adenomatous polyposis Very rare association through the APC gene

The tumours have a distinct genetic make-up. KRAS, TP53 and CDKN2A mutations, which drive most pancreatic cancers, are uncommon in acinar cell carcinoma, while defects in DNA repair genes are found more often (Ikezawa et al., 2024).

4. How does it look

On scans

Feature Description
Shape Round or oval, usually well defined
Size Often several centimetres
Content Mostly solid; larger tumours may have dead (necrotic), cystic or bleeding areas
Capsule Some have a thin enhancing rim
Ducts The main pancreatic duct is often less widened than in ductal cancer
Liver The liver is the most common site of spread

Under the microscope

Feature Description
Cells Uniform cells with granular cytoplasm and a central nucleolus
Pattern Small gland-like clusters (acini), solid sheets or trabeculae
Stroma Very little supporting fibrous tissue
Stains Positive for trypsin, chymotrypsin and BCL10
Neuroendocrine stains Usually negative or only focal, unless mixed

Special stains are essential to confirm the diagnosis, because acinar cell carcinoma can resemble a neuroendocrine tumour or a solid pseudopapillary neoplasm.

On the skin

When lipase is very high, people may develop tender red lumps on the legs caused by fat breakdown under the skin (subcutaneous fat necrosis).

5. Symptoms

Common symptoms

  • Abdominal pain, often in the upper abdomen
  • Weight loss and reduced appetite
  • Nausea, vomiting or feeling full quickly
  • Tiredness
  • Back pain

Less common symptoms

Symptom Cause
Jaundice (yellow skin and eyes) Less common than in ductal cancer, because the tumour tends to push rather than invade the bile duct
Tender skin lumps on the legs Fat necrosis from excess lipase
Painful joints Fat necrosis around joints
Diarrhoea or oily stools Reduced digestion
A lump in the abdomen Large tumour

The combination of fat necrosis, joint pain and very high lipase is known as lipase hypersecretion syndrome. It usually occurs with liver metastases.

When to seek medical advice

See your doctor if you have persistent upper abdominal or back pain, unexplained weight loss, jaundice or new tender lumps on the legs with joint pain.

6. Diagnosis

Test Purpose
CT scan with contrast Shows the tumour, blood vessels and liver
MRI Further detail of the pancreas and liver
Endoscopic ultrasound (EUS) Close-up view; allows a needle biopsy
Biopsy with special stains Confirms acinar cell carcinoma
Serum lipase Raised in about a quarter to over half of patients
AFP Occasionally raised, especially in children
CA 19-9 Often normal, unlike ductal cancer
Genetic testing of tumour and blood Looks for BRCA1/2, ATM, mismatch repair defects and BRAF fusions

Staging

Acinar cell carcinoma is staged with the same TNM system as other exocrine pancreatic cancers.

Stage General meaning
Stage I Confined to the pancreas
Stage II Larger tumour or spread to a few lymph nodes
Stage III Involves major blood vessels or many lymph nodes
Stage IV Spread to distant organs, usually the liver

About half of patients already have metastases when diagnosed.

7. Treatment

Surgery

Removing the tumour with clear margins gives the best chance of long-term control.

Operation Tumour location
Pancreaticoduodenectomy (Whipple procedure) Head of the pancreas
Distal pancreatectomy Body or tail, often with the spleen
Total pancreatectomy Very occasionally, for extensive tumours
Liver resection In selected people with limited liver spread

Even after a complete operation, the cancer often recurs, so many teams discuss additional chemotherapy, although its benefit has not been proven in trials (Ikezawa et al., 2024).

Chemotherapy

There is no standard regimen designed for acinar cell carcinoma. Doctors borrow treatments used for pancreatic and bowel cancers, which share some genetic features (Calimano-Ramirez et al., 2022).

Regimen Notes
FOLFIRINOX (5-FU, oxaliplatin, irinotecan) Often gives good responses; some complete responses reported
Gemcitabine-based combinations Used, but responses are generally lower
Capecitabine or 5-FU with oxaliplatin Bowel-cancer-type regimens
Platinum combinations Especially if BRCA or other DNA repair genes are altered

Targeted treatment

Gene change Possible treatment
BRCA1, BRCA2, PALB2 or ATM Platinum chemotherapy; PARP inhibitors such as olaparib as maintenance
BRAF fusions MEK inhibitors in selected cases or trials
Mismatch repair deficiency Immunotherapy with checkpoint inhibitors
Other rare alterations Clinical trials matched to the tumour

Because these alterations are frequent, comprehensive genomic profiling is recommended (Al-Hader et al., 2017).

Radiotherapy

Radiotherapy has a limited, unproven role. It may be considered after surgery with involved margins or for symptom control.

Side effects

Treatment Possible side effects
Pancreatic surgery Pancreatic leak, delayed stomach emptying, diabetes, poor digestion
FOLFIRINOX Tiredness, diarrhoea, nerve tingling, low blood counts
PARP inhibitors Nausea, tiredness, anaemia
Immunotherapy Rash, inflammation of the bowel, thyroid or liver

What treatment involves day to day

Stage What to expect
Before surgery Scans, blood tests and a fitness assessment; sometimes a stent to relieve jaundice
Hospital stay Usually 7-14 days after a Whipple or distal pancreatectomy
Recovery at home Several weeks of gradually increasing activity; small meals and enzyme capsules
Chemotherapy FOLFIRINOX is usually given every 2 weeks through a pump worn at home for 2 days
Tablets PARP inhibitors are taken by mouth every day, with regular blood counts

Lipase hypersecretion syndrome explained

In a small number of people, the tumour releases very large amounts of lipase, the enzyme that digests fat. When this enzyme circulates in the blood, it can break down fat in the skin, around joints and sometimes in bone marrow. The result is tender red nodules, most often on the lower legs, together with swollen, painful joints and sometimes fever.

This syndrome is uncommon, but recognising it matters, because it may be the first clue to an underlying acinar cell carcinoma. Treating the cancer, for example with chemotherapy, often improves the skin and joint symptoms.

8. Outlook (prognosis)

Acinar cell carcinoma usually has a better outlook than ductal adenocarcinoma but a poorer one than pancreatic neuroendocrine tumours. Reported median survival ranges widely, from about one and a half to four years across studies (Al-Hader et al., 2017).

Factor Effect
Complete surgical removal Best chance of long survival
Spread to the liver at diagnosis Poorer outlook
Response to chemotherapy Good responses can give years of control
DNA repair gene defects May predict better responses to platinum and PARP inhibitors
Young age Children often do better than adults

9. Follow-up

Follow-up Purpose
CT scans every 3-6 months for the first years Look for recurrence, especially in the liver
Lipase or AFP Useful if raised at diagnosis
Diabetes checks After pancreatic surgery
Nutrition review Enzyme capsules and weight monitoring
Genetic counselling If an inherited variant is found

10. Living with acinar cell carcinoma

  • Take pancreatic enzyme capsules with meals and snacks if prescribed
  • Eat small, frequent meals if you feel full quickly
  • Monitor blood sugar if you have diabetes after surgery
  • Report fever, jaundice or worsening pain promptly
  • Ask about genetic testing and what it means for your family
  • Keep active within your limits to maintain strength
  • Seek support from pancreatic cancer charities

11. Frequently asked questions

Question Answer
Is it the same as ordinary pancreatic cancer? No; it starts in different cells and behaves differently
Is the outlook better? Generally yes, especially after complete surgery
Why do I need genetic testing? Many tumours have changes that open up targeted treatments
Can children get it? Yes, rarely; outcomes are often better in children
Why does my skin hurt in lumps? High lipase can break down fat under the skin
Will I need chemotherapy after surgery? Sometimes; its benefit is uncertain and is discussed case by case
Can it come back after surgery? Yes, recurrence is common, so regular scans are important
Is it linked to smoking or alcohol? No clear link has been shown, unlike ductal pancreatic cancer

12. Questions to ask your care team

  • Has the diagnosis been confirmed with special stains?
  • Can the tumour be removed surgically?
  • Has my tumour had genomic profiling?
  • Should I have germline (blood) genetic testing?
  • Which chemotherapy do you recommend, and why?
  • Am I eligible for any clinical trials?
  • How often will I have scans?

Resources

  1. Al-Hader, A. et al. (2017) ‘Pancreatic acinar cell carcinoma: a review on molecular profiling of patient tumors’, World Journal of Gastroenterology, 23(45), pp. 7945-7951.
  2. Calimano-Ramirez, L.F. et al. (2022) ‘Pancreatic acinar cell carcinoma: a comprehensive review’, World Journal of Gastroenterology, 28(40), pp. 5827-5844.
  3. Chaudhary, P. (2015) ‘Acinar cell carcinoma of the pancreas: a literature review and update’, Indian Journal of Surgery, 77(3), pp. 226-231.
  4. Ikezawa, K. et al. (2024) ‘Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment’, Japanese Journal of Clinical Oncology, 54(3), pp. 271-281.
  5. National Cancer Institute (2026) Pancreatic Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.